Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial.
Authors : Schwarze JK, Garaud S, Jansen YJL, Awada G, Vandersleyen V, Tijtgat J, de Wind A, Kristanto P, Seremet T, Willard-Gallo K, Neyns B Year : 2022 Journal : Cancers (Basel)
A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma.
Authors : Gourari K, Catherine J, Garaud S, Kerger J, Lepida A, Georgala A, Lebrun F, Gomez Galdon M, Gil T, Willard-Gallo K, Langouo Fontsa M Year : 2022 Journal : Diagnostics (Basel)
T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy.
Authors : Garaud S, Dieu-Nosjean MC, Willard-Gallo K Year : 2022 Journal : Nat Commun
Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade.
Authors : Belcaid L, Garaud S, Kerger J, Spyridon S, Aspeslagh S Year : 2021 Journal : Acta Clin Belg
Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment.
Authors : Boisson A, Noël G, Saiselet M, Rodrigues-Vitória J, Thomas N, Fontsa ML, Sofronii D, Naveaux C, Duvillier H, Craciun L, Larsimont D, Awada A, Detours V, Willard-Gallo K, Garaud S Year : 2021 Journal : Front Mol Biosci